2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party - ScienceDirect
Role of MRD in elderly acute myeloid leukemia | CIA
The Role of Measurable Residual Disease in AML (Transcript)
Biomarkers Consortium – Measurable residual disease in acute myeloid leukemia (MRD in AML) | FNIH
NGS rEvolution - Minimal Residual Disease Detection
Monitoring of minimal residual disease in acute myeloid leukemia
Relevance of NGS-based minimal residual disease (MRD) in AML
Frontiers | Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?
Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
a Minimal residual disease (MRD) in acute myeloid leukemia (AML) using... | Download Scientific Diagram
IJMS | Free Full-Text | Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
Biomedicines | Free Full-Text | Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions
Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia | IntechOpen
MRD in AML: The Role of New Techniques | Semantic Scholar
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia | Leukemia
How Is Minimal Residual Disease (MRD) Monitored in Leukemia? | MyLeukemiaTeam
Clinical implications of measurable residual disease in AML: Review of current evidence - ScienceDirect
Role of MRD in elderly acute myeloid leukemia | CIA
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia | Leukemia
Frontiers | MRD Tailored Therapy in AML: What We Have Learned So Far
MRD Tailored Therapy in AML: What We Have Learned So Far. - Abstract - Europe PMC
The present and future of measurable residual disease testing in acute myeloid leukemia | Haematologica
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients | Haematologica
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML - ScienceDirect
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML) | Leukemia
